IMPORTANCE Coronary computed tomographic angiography (coronary CTA) can characterize coronary artery disease, including high-risk plaque. A noninvasive method of identifying high-risk plaque before major adverse cardiovascular events (MACE) could provide practice-changing optimizations in coronary artery disease care.
E valuation of stable chest pain often requires diagnostic testing with the goals of detecting obstructive coronary artery disease (CAD) and assessing the risk of a future major adverse cardiovascular event (MACE), defined as death, myocardial infarction, or unstable angina. Coronary computed tomography angiography (CTA) has developed into a reliable, noninvasive technique and a viable alternative to functional testing in outpatients with new onset of symptoms suggestive of obstructive CAD. [1] [2] [3] [4] [5] The predictive value of coronary CTA for MACE is similar to that of conventional functional testing. 4, 5 The traditional assessment of coronary CTA for obstructive CAD provides prognostic information for MACE. [6] [7] [8] However, more than half of MACEs occur in patients with nonobstructive CAD; coronary plaque detected by coronary CTA provides additional prognostic value in this group. 8 The Providing Regional Observations to Study Predictors of Events in the Coronary Tree (PROSPECT) trial, which studied coronary plaques using intravascular ultrasound in survivors of acute coronary syndrome (ACS), found that plaque characteristics (eg, a thin-cap fibroatheroma and a plaque burden >70%) were associated with 2.5-fold to 5-fold increased risk of repeat events.
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Previous research using tissue samples and intravascular imaging has defined characteristics of coronary plaques (eg, a large necrotic lipid pool, a thin fibrous cap, and a large plaque burden) that are associated with sudden cardiac death and ACS. 10, 11 Coronary CTA can characterize coronary plaques, including the detection of high-risk features such as positive remodeling, low computed tomography (CT) attenuation, or napkin-ring sign. 12,13 High-risk plaques were associated with advanced atherosclerotic plaque, thin-cap fibroatheroma, and large lipid pools, as well as with culprit lesions of ACS. [13] [14] [15] [16] [17] [18] [19] Recent studies in Japanese patients with stable chest pain suggested that the presence of high-risk plaque on coronary CTA was associated with 5-fold to 8-fold increased risk of MACE. 12, [20] [21] [22] We performed standardized core laboratory assessment of coronary CTA in a large contemporary North American population of outpatients undergoing evaluation for new-onset stable chest pain in the Prospective Multicenter Imaging Study for Evaluation of Chest Pain (PROMISE) trial (clinicaltrials.gov No. NCT01174550). We tested the hypothesis that the presence of high-risk plaque was associated with incident MACE independent of clinically significant stenosis (SS) and cardiovascular risk factors.
Methods

Study Design and Population
The PROMISE trial was a pragmatic comparative effectiveness trial that enrolled 10 003 patients at 193 sites in North America between July 2010 and September 2013. Details regarding the PROMISE study have been described elsewhere.
4,23
The study enrolled stable symptomatic outpatients without known CAD who required noninvasive cardiovascular testing. Participants were randomly assigned to either the coronary CTA or functional testing group. Patient demographics and cardiovascular risk factors were documented at the time of enrollment. Atherosclerotic cardiovascular disease (ASCVD) and Framingham Heart Study risk scores were calculated. 24, 25 After randomization, follow-up visits were performed at 60 days at the study sites and centrally at 6-month intervals for a minimum of 1 year. 4, 23 Local or central institutional review boards approved the study, and all participants provided written informed consent. In our cohort study nested in the original PROMISE trial, we included all patients who were randomized to the coronary CTA arm of the trial and who received the initial diagnostic test as randomized. (Eligible participants were randomly assigned in a ratio of 1:1 to either the anatomical or functional diagnostic testing arm of the trial. A computer-generated permuted block randomization scheme with stratification by clinical site was used. 4, 23 ) We excluded patients who received other tests as their first test, did not undergo any diagnostic test, or received noncontrast CT testing only, as well as those for whom coronary CTA data sets were unavailable or were of nondiagnostic quality (Figure 1 ).
Coronary CTA Analysis
Coronary CTA images were acquired using either retrospectively electrocardiogram-gated or prospectively electrocardiogram-triggered protocols according to guidelines and local protocols using scanners from 4 vendors (Siemens, General Electric, Toshiba, and Philips) and different generations (64-row, 128-row, 256-row, 320-row, and dual source) . 26 The images were transferred to the core laboratory for the analysis at a cardiac image-viewing workstation (TeraRecon). Six readers with level 3 training in coronary CTA were randomly assigned data sets for analysis. A further 50 randomly selected coronary CTA data sets were analyzed by all 6 readers to determine interobserver agreement (high-risk plaque: κ = 0.56; ≥70% stenosis or left main ≥50% stenosis: κ = 0.69). The coronary CTA analysis was performed per coronary segment.
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Coronary segments with nondiagnostic image quality (1602 of 79 470; 2.0%) were treated as noninformative for the analysis. Each evaluable coronary segment was assessed for the presence of stenosis. The severity of stenosis was quantified
Key Points
Question Is high-risk plaque, as detected by coronary computed tomographic angiography, associated with incident major adverse cardiovascular events?
Findings In this substudy of the PROMISE trial, we evaluated the presence of high-risk plaque in 4415 patients. High-risk plaque was present in 676 patients (15%) and carried a 70% increased risk of major adverse cardiovascular events independent of cardiovascular risk factors and obstructive coronary artery disease; detection was most useful in younger patients, women, and those with nonobstructive coronary artery disease.
Meaning
The findings suggest the potential significance of detecting high-risk plaques in patients with stable ischemic heart disease; however, the low absolute rates of major adverse cardiovascular events and low positive predictive value of high-risk plaque detection might limit its clinical applicability.
by visual estimation into 5 categories (0%, 1%-29%, 30%-49%, 50%-69%, or ≥70% stenosis). 27 We defined SS as the presence of 70% stenosis or greater in any vessel or 50% stenosis or greater in the left main coronary artery. We performed a sensitivity analysis using the definition of 50% stenosis or greater in any coronary artery as SS. Nonobstructive CAD was defined as the presence of coronary plaque with no SS. For each evaluable coronary segment, we noted the presence of plaque (calcified, noncalcified, or partially calcified; eFigure 1 in the Supplement).
28 Each coronary segment with plaque was evaluated for the presence of high-risk plaque. High-risk plaque features were defined as positive remodeling (remodeling index, >1.1), low CT attenuation (mean CT number <30 HU), or napkin-ring sign (a ringlike peripheral higher attenuation with central low CT attenuation; eFigure 1 in the Supplement). 12, 16, [18] [19] [20] [21] [29] [30] [31] Each patient was classified as having high-risk plaque if at least 1 high-risk plaque feature was present. We also performed sensitivity analyses using the definition of high-risk plaque as the presence of both positive remodeling and low CT attenuation, the presence of positive remodeling or low CT attenuation, and the presence of any 2 or 3 high-risk plaque features.
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Study Outcomes
The primary end point was a composite of time to MACE, the definition of which included death from any cause, myocardial infarction, and hospitalization for unstable angina. We performed a sensitivity analysis with MACE defined as the secondary composite end point of cardiovascular death, myocardial infarction, or hospitalization for unstable angina, and as the tertiary composite end point of death or myocardial infarction. An independent clinical events committee adjudicated all end point events in a blinded fashion on the basis of standard, prospectively determined definitions, as described previously. 
Results
Study Population
The baseline characteristics of 4415 patients included in our study are summarized in 
High-Risk Plaque Prevalence
The presence of high-risk plaque was detected in 676 patients (15.3%). Of these patients, 628 (92.9%) had positive remodeling; 222 (32.8%) had low CT attenuation; 169 (25.0%) had napkin-ring sign; 179 (26.5%) had both positive remodeling and low CT attenuation; and 671 (99.3%) had at least 1 of the high-risk plaque features of positive remodeling and low CT attenuation plaque. The prevalence of high-risk plaque in subgroups was 10.9% for women vs 20.1% for men (P < .001), 13.7% for those under median age vs 16.9% for those at or above median age (P = .004); 17.1% for those with a BMI below the median value of 30.4 vs 13.6% for those with a BMI equal to or greater than the median (P = .001); 15.1% for those without diabetes vs 16.1% for those with diabetes (P = .47); 11.9% for patients reporting no tobacco use vs 18.6% for those reporting current or past tobacco use (P < .001); and 14.4% for nonHispanic white people vs 15.5% for people of other races (P = .39).
Association of High-Risk Plaque With Nonobstructive and Obstructive CAD
The prevalence of high-risk plaque gradually increased with the increasing degree of stenosis ( The association of high-risk plaque with MACE remained significant after adjustment for SS (defined as ≥70% stenosis in any coronary artery or ≥50% stenosis in the left main coronary artery) and ASCVD risk score (aHR, 1.72; 95% CI, 1.13-2.62) (Figure 2) .
Furthermore, adding high-risk plaque to a baseline model that included SS and ASCVD risk score led to a significant continuous net reclassification improvement (0.34; 95% CI, 0.02-0.51). The C index did not increase significantly when a model including only ASCVD score and SS had high-risk plaque added to it (0.69 [95% CI, 0.63-0.74] vs 0.71 [95% CI, 0.66-0.76]; P = .12). A Grønnesby and Borgan test for goodness of fit of the model including ASCVD score, SS, and high-risk plaque was also nonsignificant, suggesting there was no gross model violation. The sensitivity, specificity, positive predictive value, and negative predictive value of high-risk plaque for MACE were 32.8%, 85.2%, 6.4%, and 97.6%, respectively. Similar results were observed when SS was defined as stenosis equal to or greater than 50% in any coronary artery (HR, 1.58; 95% CI, 1.04-2.40); when Framingham Heart Study risk score was used for adjustment (aHR, 1.68; 95% CI, 1.10-2.56); when the secondary composite end point of cardiovascular death, myocardial infarction, or hospitalization for unstable angina was used (aHR, 1.63; 95% CI, 1.01-2.62) (eFigure 2A in the Supplement); and when the tertiary composite end point of death or myocardial infarction (aHR, 1.85; 95% CI, 1.10-3.09; eFigure 2B in the Supplement) was used as the outcome.
In patients with nonobstructive CAD, in whom most incidents of MACE occurred (86 of 131; 65.6%), the presence of high-risk plaque identified a subgroup with increased risk of MACE. Of 505 patients with high-risk plaque, 24 experienced MACE (4.8%; aHR, 4.31; 95% CI, 2.25-8.26) compared with just 62 of the 2109 patients with no high-risk plaque (2.9%; aHR, 
Association of High-Risk Plaque With MACE in Subgroups
We also performed multivariable Cox proportional hazards analyses adjusted for SS and ASCVD score in patient subgroups ( Figure 3 ;eT able3intheSupplement 
Discussion
Our study demonstrated that the presence of high-risk plaque (as observed by signs such as positive remodeling, low CT attenuation, and napkin-ring sign) carried a 70% increased risk of future MACE in a large contemporary North American population of outpatients with stable chest pain, and that this risk was independent of cardiovascular risk factor burden and obstructive CAD. Detection of high-risk plaque added the most value for patients with nonobstructive CAD and those with a lower atherosclerosis burden such as younger patients and women. Our results demonstrate the clinical significance of detecting individual high-risk plaques relative to standard clinical risk factors and obstructive CAD. This suggests the potential to use this information to optimize management of this large group of patients.
High-Risk Plaque and Future MACE
Our observation of the independent predictive value of highrisk plaque for future MACE in a North American population 
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Subgroup
The analyses demonstrate the predictive value of high-risk plaque for the outcome of major adverse cardiovascular events (death, nonfatal myocardial infarction, or hospitalization for unstable angina) adjusted for significant stenosis (Ն70% stenosis in any coronary artery or Ն50% in the left main coronary artery) and atherosclerotic cardiovascular disease risk score. Error bars show adjusted hazard ratios with 95% CIs, adjusted for atherosclerotic cardiovascular disease risk score and significant stenosis. Wide and overlapping 95% CIs were present. The median age of participants was 59.6 years; median body mass index (BMI; calculated as weight in kilograms divided by height in meters squared), 29.5. Some of the differences could be explained by differences in risk profiles and clinical presentations in Japanese and North American populations (eg, lower BMIs and lower prevalence of statin treatment in the Japanese study cohorts, as well as the inclusion of some patients with CAD history in the Japanese studies). The lower predictive value of high-risk plaque also reflects temporal changes in cardiovascular disease during the last 2 decades, which includes a shift in acute coronary syndome presentations from myocardial infarctions with ST-segment elevation to those without ST-segment elevation, decrease in plaque ruptures in culprit lesions of acute coronary syndromes, and more stable characteristics of atherosclerotic plaques (eg, smaller lipid cores and less intraplaque inflammation).
33 These changes can be explained by increased use of lipid-lowering therapies (statins), better blood pressure control, and decreased prevalence of smoking; they are responsible for low MACE rates in contemporary cardiovascular clinical trials.
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However, the most striking difference, which might have significantly affected the large difference in the aHRs between our study and those completed in Japan, is the weak association of SS with MACE in the Japanese studies (aHR, 1.6-1.7). This is in contrast with our data (which found an aHR of approximately 9 for SS) and other studies from North America and Europe (which reported aHR values ranging from 3 to 9). 6, 7, 34, 35 As a result of the strong association of stenosis with MACE, there was no incremental value in high-risk plaque detection for the prediction of MACE in patients with SS. We speculate that in patients with SS the presence of stenosis plays an important role in MACE in the short term. Indeed, we observed that a significant portion of MACE occurred in the first 6 months after coronary CTA (Figure 2 ). In contrast, in patients with nonobstructive CAD and high-risk plaque, we found an increase in MACE more than 12 months after coronary CTA, suggesting that plaque progression and rupture may have played a role in the progression to these events. Because the PROMISE trial had a fairly low prevalence of obstructive CAD, the present cohort included a large number of patients who had nonobstructive CAD. This meant the study identified a large additional group of at-risk patients, in whom over half of MACEs occurred. 8 Our results are in agreement with extensive research in interventional cardiology that has found that a significant number of MACEs occur at locations in the coronary artery tree where previously no obstructive CAD was present. [36] [37] [38] Indeed, the presence of high-risk plaque doubles the risk of MACE in the group of patients with nonobstructive CAD, and this provides considerably more information. Since the presence of high-risk plaque can be easily determined during routine evaluation of coronary CTA and because it permits risk reclassification especially in younger patients and women, information on the presence of high-risk plaque should be included in standardized reports in accordance with the current guideline recommendations.
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High-Risk Plaque in Patient Subgroups
The large size of our population permitted subgroup analyses that provided additional insights into the role of high-risk plaque for MACE prediction. We observed that the predictive value of highrisk plaque was stronger in younger patients and women. Women with CAD tend to have lower coronary plaque burden but also smaller size of coronary arteries, which may lead to symptomatic disease with lower plaque burden or thrombus load. [40] [41] [42] [43] [44] [45] Previous studies of differences in coronary plaque development in men and women have suggested that lower prevalence of plaque ruptures and thin-cap fibroatheroma but higher prevalence of plaque erosions exist in women; however, these results have not been consistent across studies. 41, [46] [47] [48] [49] Sex-based differences in plaque size and composition have been more pronounced in younger women and more attenuated in women older than 65 years.
43,49
We speculate that when high-risk plaques are present in younger women, they portend a higher risk of future MACE. Furthermore, younger patients and women have a lower prevalence of obstructive CAD, and thus, consistent with our findings, high-risk plaque may be most helpful for risk stratification in patients without SS.
Local Interventional Treatment of High-Risk Plaque
The results of our study challenge the feasibility of local therapies for high-risk plaque. We found that only 6.4% of patients with high-risk plaque developed MACE and that, among 131 patients with MACEs, 88 patients (67.2%) had no high-risk plaque. These results are similar to observations from the PROSPECT trial, in which only 26 of 595 patients (4.9%) with thin-cap fibroatheromata experienced the development of culprit lesions of acute coronary syndrome. 9 Therefore, local interventional therapies for high-risk plaque may be of limited value. Overall, the presence of high-risk plaque, especially in those with nonobstructive CAD, may constitute an additional risk stratification tool guiding management, including lifestyle modification (eg, diet and exercise) and pharmacologic treatments (eg, treatment with lipidlowering and antiplatelet therapies).
Limitations
In the setting of low MACE rates observed in the PROMISE trial, HRs may inflate the importance of our observations. This is especially true given the low positive predictive value of high-risk plaque for MACE. The options for changes in preventive therapies (eg, aspirin or statin) based on the detection of high-risk plaque by coronary CTA are limited, and no data on whether such interventions would change long-term outcomes are available from our study. The PROMISE trial was not a study of natural history, and patients were treated based on coronary CTA results, which might have affected MACE. We performed a qualitative analysis of high-risk plaque with simple manual measurements that can be easily incorporated into clinical practice. An identical approach was used by other investigators studying the predictive value of high-risk plaque. 12,21 Quantitative plaque assess-ment is feasible but remains time-consuming, not widely used in clinical practice, and of unproven value.
Conclusions
In a large contemporary North American population of outpatients with stable chest pain, noninvasive detection of high-risk plaque improved risk assessment for MACE. The detection of high-risk plaque added the most value in patients with nonobstructive CAD, younger patients, and women. High-risk plaque may constitute an additional risk stratification tool for clinical management. However, because absolute event rates were low and the positive predictive value of high-risk plaque was diminished, the findings may be of limited applicability to clinical management strategies. Coronary CTA images were evaluated in axial and multiplanar reformatted images. Panel A Any structure with a density of ≥130 HU that could be visualized separately from the contrast-enhanced coronary lumen, could be assigned to the coronary artery wall, and could be identified in at least two independent planes was defined as calcified plaque (arrow). The image shows calcified plaque in the proximal left anterior descending coronary artery and the degree of stenosis was graded as 1-29%. Panel B If both calcified (arrowhead) and non-calcified plaque components were present, the plaque was classified as partially calcified. The partially calcified plaque in the mid right coronary artery was causing 70-99% stenosis (arrow). Panel C Non-calcified coronary plaque was defined as any discernible structure that could be assigned to the coronary artery wall, had a CT number below the contrast-enhanced coronary lumen, but above the surrounding connective tissue, and could be identified in at least two independent planes. The example shows non-calcified plaque (arrowheads) in the left circumflex coronary artery with 30-49% stenosis. This example also shows a high-risk plaque feature of low CT attenuation. If low CT attenuation was visually noted in non-calcified plaque, readers placed three random region-of-interest measurements (approximately 0.5-1.0 mm 2 ) in the non-calcified low CT attenuation portion of the plaque. Low CT attenuation plaque was defined as the mean CT number within these three regions of interest <30 HU. Panel D Large non-calcified plaque (arrow) in the proximal left anterior descending coronary artery with positive remodeling. Panel E Positive remodeling was assessed visually in multiplanar reformatted images reconstructed in long axis and short axis view of the vessel. Additional manual measurements of outer vessel diameter were performed at readers' discretion and threshold of 1.1 (ratio of outer vessel diameter at the plaque site -arrow -divided by outer vessel diameter at reference sitearrowhead) was used to define positive remodeling. Panel F The napkin ring sign was defined as a ring-like peripheral higher attenuation (arrowhead) with central low CT attenuation non-calcified portion of the coronary plaque (arrow) 
